Blueprint Medicines Dirección
Dirección controles de criterios 3/4
El CEO de Blueprint Medicines' es Kate Haviland , nombrado en Apr 2022, tiene una permanencia de 2.08 años. compensación anual total es $6.43M, compuesta por 12.2% salario y 87.8% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.095% de las acciones de la empresa, por valor de $5.47M. La antigüedad media del equipo directivo y de la junta directiva es de 3.7 años y 9 años, respectivamente.
Información clave
Kate Haviland
Chief Executive Officer (CEO)
US$6.4m
Compensación total
| Porcentaje del salario del CEO | 12.2% |
| Permanencia del CEO | 2.1yrs |
| Participación del CEO | 0.1% |
| Permanencia media de la dirección | 3.7yrs |
| Promedio de permanencia en la Junta Directiva | 9yrs |
Actualizaciones recientes de la dirección
Recent updates
Is Blueprint Medicines (NASDAQ:BPMC) Using Debt In A Risky Way?
Apr 26
Risks To Shareholder Returns Are Elevated At These Prices For Blueprint Medicines Corporation (NASDAQ:BPMC)
Apr 05Blueprint Medicines: Ayvakit Revenue Surge Fuels Optimism (Rating Upgrade)
Feb 20Blueprint Medicines Corporation (NASDAQ:BPMC) Shares Could Be 29% Below Their Intrinsic Value Estimate
Jan 08Subdued Growth No Barrier To Blueprint Medicines Corporation (NASDAQ:BPMC) With Shares Advancing 38%
Dec 18Is Blueprint Medicines (NASDAQ:BPMC) Weighed On By Its Debt Load?
Nov 20Is Blueprint Medicines (NASDAQ:BPMC) Using Debt Sensibly?
Jul 26Health Check: How Prudently Does Blueprint Medicines (NASDAQ:BPMC) Use Debt?
Apr 16Is Blueprint Medicines Corporation (NASDAQ:BPMC) Expensive For A Reason? A Look At Its Intrinsic Value
Jan 09Despite Lacking Profits Blueprint Medicines (NASDAQ:BPMC) Seems To Be On Top Of Its Debt
Dec 12Need To Know: Analysts Just Made A Substantial Cut To Their Blueprint Medicines Corporation (NASDAQ:BPMC) Estimates
Nov 07Blueprint Medicines: Royalties Being Sold Allows For More Shots On Goal
Sep 15Blueprint to seek label expansion for systemic mastocytosis therapy after trial win
Aug 17Blueprint Medicines reports Q2 earnings miss; reaffirms FY22 guidance
Aug 02Blueprint to sell Ayvakit royalty for $250M upfront; Gavreto royalty for $175M upfront
Jun 30Time To Worry? Analysts Just Downgraded Their Blueprint Medicines Corporation (NASDAQ:BPMC) Outlook
Feb 17Here's Why We're Not Too Worried About Blueprint Medicines' (NASDAQ:BPMC) Cash Burn Situation
Nov 10Calculating The Intrinsic Value Of Blueprint Medicines Corporation (NASDAQ:BPMC)
Oct 15Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$288m |
| Dec 31 2023 | US$6m | US$782k | -US$507m |
| Sep 30 2023 | n/a | n/a | -US$555m |
| Jun 30 2023 | n/a | n/a | -US$554m |
| Mar 31 2023 | n/a | n/a | -US$581m |
| Dec 31 2022 | US$6m | US$701k | -US$558m |
| Sep 30 2022 | n/a | n/a | -US$718m |
| Jun 30 2022 | n/a | n/a | -US$702m |
| Mar 31 2022 | n/a | n/a | -US$650m |
| Dec 31 2021 | US$4m | US$501k | -US$644m |
| Sep 30 2021 | n/a | n/a | -US$411m |
| Jun 30 2021 | n/a | n/a | US$340m |
| Mar 31 2021 | n/a | n/a | US$325m |
| Dec 31 2020 | US$2m | US$461k | US$314m |
| Sep 30 2020 | n/a | n/a | US$333m |
| Jun 30 2020 | n/a | n/a | -US$395m |
| Mar 31 2020 | n/a | n/a | -US$371m |
| Dec 31 2019 | US$3m | US$432k | -US$348m |
| Sep 30 2019 | n/a | n/a | -US$362m |
| Jun 30 2019 | n/a | n/a | -US$340m |
| Mar 31 2019 | n/a | n/a | -US$267m |
| Dec 31 2018 | US$3m | US$393k | -US$237m |
| Sep 30 2018 | n/a | n/a | -US$205m |
| Jun 30 2018 | n/a | n/a | -US$170m |
| Mar 31 2018 | n/a | n/a | -US$177m |
| Dec 31 2017 | US$1m | US$353k | -US$148m |
Compensación vs. Mercado: La compensación total ($USD6.22M) de Kate está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD8.28M).
Compensación vs. Ingresos: La compensación de Kate ha aumentado mientras la empresa no es rentable.
CEO
Kate Haviland (47 yo)
2.1yrs
Permanencia
US$6,432,012
Compensación
Ms. Kathryn Haviland, also known as Kate, is Director of Bicara Therapeutic, Inc. from October 2023. She has been a Director of Fulcrum Therapeutics, Inc. since June 27, 2018. She serves as President, Chie...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 2.1yrs | US$6.43m | 0.095% $ 6.4m | |
| Co-Founder & Director | no data | US$397.33k | 0.11% $ 7.4m | |
| Chief Financial Officer | 8.3yrs | US$2.19m | 0.025% $ 1.7m | |
| Chief Operating Officer | 2.1yrs | US$2.81m | 0.043% $ 2.9m | |
| Chief Scientific Officer | 3yrs | US$2.30m | 0.077% $ 5.2m | |
| President of Research & Development | 3.7yrs | US$2.80m | 0.044% $ 2.9m | |
| Senior VP | 1.3yrs | sin datos | 0.024% $ 1.6m | |
| Chief Technical Operations & Quality Officer | 6.6yrs | US$3.79m | 0.054% $ 3.6m | |
| Senior Director & Head of Investor Relations | no data | sin datos | sin datos | |
| Executive VP | 7.7yrs | US$2.34m | 0.046% $ 3.1m | |
| Chief People Officer | 4.3yrs | sin datos | 0.042% $ 2.8m | |
| Senior Vice President of Corporate Affairs | no data | sin datos | sin datos |
3.7yrs
Permanencia media
52yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de BPMC se considera experimentado (3.6 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 2.1yrs | US$6.43m | 0.095% $ 6.4m | |
| Co-Founder & Director | 13.1yrs | US$397.33k | 0.11% $ 7.4m | |
| Chair of Scientific Advisory Board | 12yrs | US$333.38k | sin datos | |
| Lead Independent Director | 8.1yrs | US$452.33k | 0.013% $ 900.0k | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board & Independent Director | 13.1yrs | US$417.33k | 0.085% $ 5.7m | |
| Independent Director | 8.3yrs | US$419.33k | 0.013% $ 900.0k | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 2.4yrs | US$422.33k | 0.0059% $ 399.2k | |
| Chairman | 9.8yrs | US$526.08k | 0.24% $ 15.9m |
9.0yrs
Permanencia media
61yo
Promedio de edad
Junta con experiencia: La junta directiva de BPMC se considera experimentada (9 años de antigüedad promedio).